Literature DB >> 22847470

Connective tissue diseases: Management of lupus nephritis-new guidelines revealed.

Ellen Ginzler1.   

Abstract

The past decade has seen exciting progress in the management of lupus nephritis, a manifestation of systemic lupus erythematosus that accounts for its major morbidity and mortality. The American College of Rheumatology has issued new guidelines for screening and treatment of lupus nephritis, based on expert recommendations.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22847470     DOI： 10.1038/nrrheum.2012.131

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


  8 in total

1.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis.

Authors:  Bevra H Hahn; Maureen A McMahon; Alan Wilkinson; W Dean Wallace; David I Daikh; John D Fitzgerald; George A Karpouzas; Joan T Merrill; Daniel J Wallace; Jinoos Yazdany; Rosalind Ramsey-Goldman; Karandeep Singh; Mazdak Khalighi; Soo-In Choi; Maneesh Gogia; Suzanne Kafaja; Mohammad Kamgar; Christine Lau; William J Martin; Sefali Parikh; Justin Peng; Anjay Rastogi; Weiling Chen; Jennifer M Grossman
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-06       Impact factor: 4.794

2.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis.

Authors:  Ellen M Ginzler; Mary Anne Dooley; Cynthia Aranow; Mimi Y Kim; Jill Buyon; Joan T Merrill; Michelle Petri; Gary S Gilkeson; Daniel J Wallace; Michael H Weisman; Gerald B Appel
Journal:  N Engl J Med       Date:  2005-11-24       Impact factor: 91.245

Review 3.  Lupus nephritis: induction therapy in severe lupus nephritis--should MMF be considered the drug of choice?

Authors:  Brad H Rovin; Samir V Parikh; Lee A Hebert; Tak Mao Chan; Chi Chiu Mok; Ellen M Ginzler; Lai Seong Hooi; Paul Brunetta; Romeo Maciuca; Neil Solomons
Journal:  Clin J Am Soc Nephrol       Date:  2012-08-09       Impact factor: 8.237

4.  Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis.

Authors:  Tak-Mao Chan; Kai-Chung Tse; Colin Siu-On Tang; Mo-Yin Mok; Fu-Keung Li
Journal:  J Am Soc Nephrol       Date:  2005-02-23       Impact factor: 10.121

5.  Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.

Authors:  Mary Anne Dooley; David Jayne; Ellen M Ginzler; David Isenberg; Nancy J Olsen; David Wofsy; Frank Eitner; Gerald B Appel; Gabriel Contreras; Laura Lisk; Neil Solomons
Journal:  N Engl J Med       Date:  2011-11-17       Impact factor: 91.245

6.  Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study.

Authors:  Brad H Rovin; Richard Furie; Kevin Latinis; R John Looney; Fernando C Fervenza; Jorge Sanchez-Guerrero; Romeo Maciuca; David Zhang; Jay P Garg; Paul Brunetta; Gerald Appel
Journal:  Arthritis Rheum       Date:  2012-01-09

7.  Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.

Authors:  Gerald B Appel; Gabriel Contreras; Mary Anne Dooley; Ellen M Ginzler; David Isenberg; David Jayne; Lei-Shi Li; Eduardo Mysler; Jorge Sánchez-Guerrero; Neil Solomons; David Wofsy
Journal:  J Am Soc Nephrol       Date:  2009-04-15       Impact factor: 10.121

8.  Azathioprine versus mycophenolate mofetil for long-term immunosuppression in lupus nephritis: results from the MAINTAIN Nephritis Trial.

Authors:  Frédéric A Houssiau; David D'Cruz; Shirish Sangle; Philippe Remy; Carlos Vasconcelos; Radmila Petrovic; Christoph Fiehn; Enrique de Ramon Garrido; Inge-Magrethe Gilboe; Maria Tektonidou; Daniel Blockmans; Isabelle Ravelingien; Véronique le Guern; Geneviève Depresseux; Loïc Guillevin; Ricard Cervera
Journal:  Ann Rheum Dis       Date:  2010-09-10       Impact factor: 19.103
  8 in total
  2 in total

1.  Lupus nephritis: Transatlantic management recommendations compared.

Authors:  Falk Hiepe
Journal:  Nat Rev Rheumatol       Date:  2012-11-13       Impact factor: 20.543

2.  Nephritis, cerebritis, and myositis after adalimumab therapy in a patient with rheumatoid arthritis: a case report.

Authors:  Narges E Omran; Abdulsalam A Noorwali
Journal:  Int J Gen Med       Date:  2018-04-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.